Rapport Therapeutics
RAPP
82 hedge funds and large institutions have $438M invested in Rapport Therapeutics in 2025 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 28 increasing their positions, 19 reducing their positions, and 9 closing their positions.
67% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 9
47% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 19
15% more capital invested
Capital invested by funds: $382M → $438M (+$55.6M)
6% more funds holding
Funds holding: 77 → 82 (+5)
1.08% more ownership
Funds ownership: 104.39% → 105.47% (+1.1%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $10K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$5.84M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$4.8M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$2.22M |
| 4 |
AAA
Affinity Asset Advisors
New York
|
+$2.12M |
| 5 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$1.91M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$9.95M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$3.81M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$2.5M |
| 4 |
Swiss National Bank
Zurich,
Switzerland
|
-$320K |
| 5 |
California State Teachers Retirement System (CalSTRS)
West Sacramento,
California
|
-$306K |
RAPP Hedge Fund Activity: Q2 2025 in Review
82 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Rapport Therapeutics (RAPP) for Q2 2025, worth a combined $438M — up 15% from $382M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new RAPP positions and 9 closed out — a net gain of 6 holders — while 28 added to existing stakes and 19 trimmed.
The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $5.84M. The largest seller was T. Rowe Price Investment Management, cutting an estimated $9.95M.
- 82 institutional investors held Rapport Therapeutics (RAPP) as of Q2 2025, up from 77 in Q1 2025.
- Funds reported $438M of Rapport Therapeutics stock for Q2 2025, up 15% quarter-over-quarter.
- 15 funds opened new Rapport Therapeutics positions in Q2 2025 and 9 closed out, a net change of +6 holders.
- The largest Rapport Therapeutics buyer in Q2 2025 was Baker Bros. Advisors, an estimated $5.84M added.
- The largest Rapport Therapeutics seller in Q2 2025 was T. Rowe Price Investment Management, an estimated $9.95M sold.
Based on aggregated 13F filings for Q2 2025.